Follow-up experiments revealed that combined treatment of the PERK inhibitor with immune checkpoint blockage/anti Programmed Cell Death Protein 1 (PD-1) immunotherapy enhance the antitumor efficacy in tumor bearing mice. Here, PDCD1 is linked to neoplasm.